Talkspace (TALK) Q1 2025 Earnings Call May 06, 2025 08:30 AM ET Company Participants Jeannine Feyen - Director of CommunicationsJon Cohen - Chief Executive OfficerIan Harris - Chief Financial OfficerRyan Daniels - Group Head–Healthcare Technology and ServicesSteve Dechert - AVPCharles Rhyee - Managing Director Conference Call Participants Bobby Brooks - Vice President, Senior Equity Research AnalystRyan Macdonald - Senior AnalystSteven Valiquette - MD & Senior Equity Research Analyst - Covering Health Care ...

SiriusPoint (SPNT) Q1 2025 Earnings Call May 06, 2025 08:30 AM ET Company Participants Liam Blackledge - Investor Relations and Strategy ManagerScott Egan - CEOJim McKinney - CFO Operator Good morning, ladies and gentlemen, and welcome to Series Point's First Quarter twenty twenty five Earnings Conference Call. During today's presentation, all parties will be in a listen only mode. As a reminder, this conference call is being recorded and a replay is available through 11:59 p. M. Eastern Time on 05/20/2025. ...

Ranpak (PACK) Q1 2025 Earnings Call May 06, 2025 08:30 AM ET Company Participants Sara Horvath - Executive VP, Chief Legal & HR OfficerOmar Asali - Chairman and Chief Executive OfficerWilliam Drew - EVP & CFO Conference Call Participants Danny Eggerichs - Equity Research AnalystNone - Analyst Operator Good morning, and welcome to the Randpak Holdings Corp. First Quarter twenty twenty five Earnings Call. All participants are in a listen only mode. After the speakers' remarks, we will conduct a question and a ...

Orthofix Medical (OFIX) Q1 2025 Earnings Call May 06, 2025 08:30 AM ET Company Participants Julie Dewey - Chief Investor Relations & Communications OfficerMassimo Calafiore - President, CEO & DirectorJulie Andrews - Chief Financial OfficerIseult McMahon - Equity Research AssociateMathew Blackman - Managing DirectorCaitlin Cronin - DirectorJeffrey Cohen - MD - Equity Research Operator Thank you for standing by. My name is Tina, and I will be your conference operator today. At this time, I would like to welco ...

Omnicell (OMCL) Q1 2025 Earnings Call May 06, 2025 08:30 AM ET Company Participants Kathleen Nemeth - Senior Vice President, Investor RelationsRandall Lipps - Founder, Executive Chairman, President & CEONchacha Etta - Executive VP & CFONnamdi Njoku - EVP & COOBill Sutherland - Director of ResearchDavid Larsen - Managing Director Conference Call Participants Jessica Tassan - Senior Equity Research AnalystGene Mannheimer - Managing Director, Senior Research AnalystAllen Lutz - Senior Equity Research AnalystSt ...

Financial Data and Key Metrics Changes - Total revenue for Q1 2025 was $32 million, an increase of 84% compared to $17.4 million in Q1 2024, primarily driven by the Greenbrook acquisition [6][21] - Gross margin decreased to 49% from 75% in the prior year quarter, mainly due to the inclusion of Greenbrook's lower-margin clinic business [22] - Net loss for the quarter was $12.7 million, or $0.21 per share, compared to a net loss of $7.9 million, or $0.27 per share, in the prior year quarter [23] - EBITDA was negative $10.1 million compared to negative $6.3 million in the prior year quarter [23] Business Line Data and Key Metrics Changes - NeuroStar system revenue was $2.8 million with 31 systems shipped [7] - US treatment session revenue was $9.6 million, a decrease of 26% year over year due to the elimination of Greenbrook treatment session revenue [21] - US clinic revenue, representing Greenbrook revenue, was $18.7 million for the quarter, reflecting strong performance [21] Market Data and Key Metrics Changes - Greenbrook's total clinic revenue increased by 41% year over year, from approximately $139,000 in Q1 2024 to approximately $196,000 in Q1 2025 [11] - NeuroStar TMS revenue at Greenbrook clinics increased by 8% year over year [11] Company Strategy and Development Direction - The company is focused on two strategic priorities: executing the Greenbrook integration and growth strategy, and scaling the Better Meat Provider (BMP) program [7][13] - The rollout of SPRAVATO is progressing, with 75% of Greenbrook clinics now offering it as a treatment option [9] - The BMP program is gaining momentum, with over 385 active sites and another 110 sites working to meet program standards [13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving cash flow positivity by Q3 2025, supported by revenue growth initiatives and operational improvements [12][29] - The macro environment is expected to have a negligible impact on the business, with limited effects from tariffs [25] Other Important Information - The company has identified approximately $22.5 million of annualized synergies from the Greenbrook acquisition, with 95% realized by the end of 2024 [12] - The company is actively looking for additional synergy opportunities, expecting total realized synergies to exceed $23 million [12] Q&A Session Summary Question: Can you provide insights on BMP sites and their utilization trends? - Management noted a natural dip in the funnel due to an influx of new accounts entering the BMP program, but expects to build the pipeline back up [34][38] Question: What are the expectations for Greenbrook and NeuroStar utilization? - Greenbrook's utilization per NeuroStar chair increased to just under five patients per day, with growth expected to continue [41][42] Question: Can you clarify the revenue guidance for the year? - The guidance remains at $65 million to $70 million for Neuronetics and $80 million to $85 million for Greenbrook [58] Question: What is the expected operating expense for Q2? - The normalized operating expense for Q2 is expected to be in the range of $23 million to $24 million [54] Question: How will the gross margin evolve in the coming quarters? - Management anticipates a nice improvement in gross margin in Q2 and Q3, approaching the 55% target [62]

Lindblad Expeditions (LIND) Q1 2025 Earnings Call May 06, 2025 08:30 AM ET Company Participants Rick Goldberg - CFONatalya Leahy - CEOSteven Wieczynski - Managing Director Conference Call Participants David Hargreaves - Analyst Operator and thank you for standing by. At this time, I would like to welcome you to the Litblad Expeditions Holdings, Inc. Reports twenty twenty five First Quarter Financial Results. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, the ...

LCI Industries (LCII) Q1 2025 Earnings Call May 06, 2025 08:30 AM ET Company Participants Lillian Etzkorn - Executive VP & CFOJason Lippert - CEO, President & DirectorDaniel Moore - Partner - Director of ResearchMichael Swartz - Director - Equity ResearchJack Weisenberger - Equity Research AssociateBret Jordan - Managing Director Conference Call Participants Joseph Altobello - Equity Research AnalystCraig Kennison - Director of Research Operations & Senior Research AnalystTristan Thomas-Martin - Leisure Ana ...

Krystal Biotech (KRYS) Q1 2025 Earnings Call May 06, 2025 08:30 AM ET Company Participants Stéphane Paquette - VP - Business DevelopmentKrish Krishnan - Chairman & CEOJennifer McDonough - SVP of Patient Access, Analytics & OperationsChristine Wilson - Head of U.S. Sales & MarketingSuma Krishnan - President, Research & DevelopmentKathryn Romano - Executive VP & Chief Accounting OfficerAlec Stranahan - Vice President - Equity ResearchGavin Clark-Gartner - Director - Biotechnology Equity ResearchAndrea Newkirk ...

Kontoor Brands (KTB) Q1 2025 Earnings Call May 06, 2025 08:30 AM ET Company Participants Michael Karapetian - Vice President of Corporate Development, Strategy, and Investor RelationsScott Baxter - President, Chief Executive Officer and Chair of the BoardJoe Alkire - EVP & CFOBrooke Roach - Vice President - Equity ResearchPaul Kearney - VP - Equity ResearchPeter McGoldrick - Equity Research Associate Conference Call Participants Ike Boruchow - Managing Director: Senior Analyst - Retailing, Specialty Softlin ...